ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0810

Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis

María Paula Álvarez Hernández1, Alejandro Gómez Gómez2, Lara Borrego Sanz3, Rosalía Méndez Fernández3, Pedro Arriola Villalobos3, Esperanza Pato Cour4, David Díaz Valle3 and Luis Rodriguez-Rodriguez4, 1Hospital Clínico San Carlos, Madrid, Spain, 2Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, 3Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, 4Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Disease-Modifying Antirheumatic Drugs (Dmards), Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Non-infectious uveitis (NIUs) encompass a varied group of inflammatory diseases affecting the uvea and adjacent tissues, with evidence suggesting an immune-mediated cause. A correct management of these conditions is essential to prevent visual loss and the development of ocular complications. Although immunosuppressive drugs (ISDs) have shown effectiveness in achieving a sustained control of the inflammatory process, not all patients achieve a satisfactory response.

To identify factors affecting the response rate to ISDs in subjects with NIUs.

Methods: Longitudinal retrospective study, with patients collected from the Hospital Clinico San Carlos Uveitis Clinic, included from 1991 until December 2018, and followed-up until December 2019. Patients entered the study at ISD prescription and were followed-up until a) the achievement of a good therapeutic response (GTR), b) ISD treatment change (withdrawal of the prescribed ISD and/or addition of a new ISD), c) 12 months of follow-up, or d) loss of follow-up or end of the study (December 31th, 2019). GTR was defined as the complete resolution of the eye inflammatory manifestations and oral corticosteroid ≤10 mg of prednisone equivalent a day. Furthermore, this situation had to be maintained in at least two consecutive visits spanned at least 28 days. KaplanMeier (KM) curves were set to account for GTR. Associated demographic, clinical and treatmentrelated factors were analyzed using bivariate and multivariate Cox robust regression models. Different models were compared using the Akaike Information Criteria, to select the fittest model to the data. Proportional hazard assumption was tested using Schoenfeld residuals and the scaled Schoenfeld residuals. In case a variable or certain category of a categorical variable were nonproportional, they were included in the Cox models with a time-varying effect, in case the interaction with time was significant (p< 0.05).

Results: 73 patients (100 episodes of ISD prescription) were analyzed. In 44 episodes, a GTR was achieved (incidence rate 102.0 [95% Confidence Interval (CI): 75.9 to 137.1] per 100 patient-years). Figure 1 shows the KM curve for GTR. In the bivariate analysis, several variables showed a significant association with GTR, including gender, diagnosis of Behçet Disease, prescription of Cyclosporine A (CYA), number of previously prescribed ISDs, previous use of the same ISD, previous discontinuation of a ISD due to inefficacy, higher systemic corticosteroid use in the previous year before ISD prescription, presence of macular edema (ME), and longer intermediate and posterior activity before ISD prescription. Table 1 shows the results of the multivariate analysis. Prescription of CYA was associated with a higher hazard of GTR, compared with the use of other ISDs (methotrexate, azathioprine or biologic drugs). In addition, the higher dosage of oral corticosteroids used in the previous year before ISD prescription, the lower the hazard of achieving a GTR. Finally, presence of ME at prescription was associated with lower hazard of GTR, although this risk diminished with time.

Conclusion: We have identified several variables associated with therapeutic response to ISDs in NIUs patients.

Supporting image 1

Multivariate Cox robust regression to analyze variables independently associated with the achievement of good therapeutic response.

Supporting image 2

Kaplan-Meier failure curves representing good therapeutic response after immunosuppressive drug prescription for non-infectious uveitis.


Disclosures: M. Álvarez Hernández, None; A. Gómez Gómez, None; L. Borrego Sanz, None; R. Méndez Fernández, None; P. Arriola Villalobos, None; E. Pato Cour, None; D. Díaz Valle, None; L. Rodriguez-Rodriguez, None.

To cite this abstract in AMA style:

Álvarez Hernández M, Gómez Gómez A, Borrego Sanz L, Méndez Fernández R, Arriola Villalobos P, Pato Cour E, Díaz Valle D, Rodriguez-Rodriguez L. Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/analysis-of-factors-associated-with-good-therapeutic-response-to-immunosuppressive-drugs-in-patients-with-non-infectious-uveitis-a-survival-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-factors-associated-with-good-therapeutic-response-to-immunosuppressive-drugs-in-patients-with-non-infectious-uveitis-a-survival-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology